Lymphokines Or Monokines Patents (Class 435/69.5)
-
Patent number: 7312079Abstract: Polynucleotide and polypeptide sequences that encode novel variant FAM3C proteins are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.Type: GrantFiled: October 4, 2006Date of Patent: December 25, 2007Assignee: Lexicon Pharmaceuticals, Inc.Inventor: Yi Hu
-
Patent number: 7309781Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: May 27, 2004Date of Patent: December 18, 2007Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7300774Abstract: A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity.Type: GrantFiled: December 9, 1999Date of Patent: November 27, 2007Assignee: The Regents of the University of CaliforniaInventor: Richard S. Kornbluth
-
Patent number: 7285620Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: May 19, 2005Date of Patent: October 23, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Patent number: 7276576Abstract: An isolated and substantially pure mammal polypeptide different from known adrenergic, serotonine and dopamine receptors, existing at least on mammalian muscle and eosinophils membranes, for instance in rat, guinea pig and humans. The invention also relates to plasmids containing the genes coding for said polypeptide, to host cells transformed by genes coding for the above mentioned polypeptide, to nucleotide probes capable of hybridizing with the genes coding for the above mentioned polypeptide, and to polyclonal and monoclonal antibodies directed against the above mentioned polypeptide.Type: GrantFiled: December 12, 1997Date of Patent: October 2, 2007Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Gerlinde Lenzen, Arthur Donny Strosberg, Toshinari Sugasawa, Shigeaki Morooka
-
Patent number: 7271246Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: July 20, 2006Date of Patent: September 18, 2007Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
-
Patent number: 7250275Abstract: The present invention is to provide a chicken LIF gene. Based on this genetic information, LIF protein derived from the chicken can be stably supplied and it solves the problems of the creation of transgenic chickens in the past. In addition, the present invention provides not only transgenic chickens for testing purposes but also supplies the first practical transgenic stock animals. The present invention relates to leukemia inhibitory factor (LIF) shown in sequence No. 2, and the gene that encodes thereof shown in sequence No. 1, and a manufacturing method of chicken LIF. In addition, the present invention pertains to a differential preventer of the chicken differentiable cell, and a method of chicken differential prevention and a culturing method for the chicken differentiable cell using thereof, and a medium comprising thereof.Type: GrantFiled: April 11, 2005Date of Patent: July 31, 2007Assignee: Hiroshima UniversityInventors: Haruo Matsuda, Shuichi Furusawa, Hiroyuki Horiuchi
-
Patent number: 7250161Abstract: Disclosed and/or claimed is subject matter including: equine GM-CSF, its amino acid sequence, nucleic acid molecules encoding equine GM-CSF, use of equine GM-CSF as an adjuvant or non-specific immunity stimulant, compositions containing equine GM-CSF and vectors expressing GM-CSF.Type: GrantFiled: July 7, 2003Date of Patent: July 31, 2007Assignee: Uerial LLCInventors: Michel Bublot, Jennifer Maria Perez, Christine Michele Pierrette Andreoni
-
Patent number: 7250169Abstract: Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.Type: GrantFiled: August 25, 2003Date of Patent: July 31, 2007Assignee: University of ConnecticutInventors: Thomas T. Chen, Maria J. M. Chen
-
Patent number: 7250274Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.Type: GrantFiled: December 12, 2003Date of Patent: July 31, 2007Assignee: ZymoGenetics, Inc.Inventors: Chung Chan, Bruce L. Zamost, Douglas C. Covert, Hong Y. Liu, Karen S. De Jongh, Jeffrey D. Meyer, Susan D. Holderman
-
Patent number: 7244823Abstract: The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.Type: GrantFiled: September 30, 2002Date of Patent: July 17, 2007Assignee: XencorInventors: Bassil I. Dahiyat, John R. Desjarlais, Anton Filikov, Umesh Muchhal, Malu Lourdes G. Tansey, Jonathan Zalevsky
-
Patent number: 7241736Abstract: Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.Type: GrantFiled: May 12, 2005Date of Patent: July 10, 2007Assignee: Angiotech International AGInventors: William L Hunter, Philip M Toleikis, David M Gravett, Rui Avelar, Dechi Guan
-
Patent number: 7232885Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: February 5, 2004Date of Patent: June 19, 2007Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7217788Abstract: The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.Type: GrantFiled: October 11, 2002Date of Patent: May 15, 2007Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz
-
Patent number: 7214779Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: February 5, 2004Date of Patent: May 8, 2007Assignee: Bolder Biotechnology Inc.Inventor: George N. Cox, III
-
Patent number: 7202029Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.Type: GrantFiled: September 25, 2002Date of Patent: April 10, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 7198918Abstract: A polypeptide which contains the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing encoded by a gene originating in human being. Because of serving as a chemical efficacious in the suppression of the proliferation and differentiation of undifferentiated blood cells, this polypeptide is expected to be usable in medicines and medical supplies.Type: GrantFiled: January 27, 2005Date of Patent: April 3, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Seiji Sakano, Akira Itoh
-
Patent number: 7198793Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 3, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7153943Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: November 15, 2002Date of Patent: December 26, 2006Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7153937Abstract: Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.Type: GrantFiled: September 24, 2002Date of Patent: December 26, 2006Assignee: ZymoGenetics, Inc.Inventors: Scott R. Presnell, Teresa Gilbert, Theresa Martinez, Ross C. Hoffman
-
Patent number: 7153512Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: December 26, 2006Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7150875Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: March 18, 2002Date of Patent: December 19, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
-
Patent number: 7150873Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.Type: GrantFiled: November 26, 2003Date of Patent: December 19, 2006Assignee: Intervet International B.V.Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
-
Patent number: 7148333Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: March 26, 2003Date of Patent: December 12, 2006Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7144987Abstract: The invention relates to novel proteins with TNF-receptor antagonist activity and nucleic acids encoding these proteins. The invention further relates to TNF-receptor proteins with reduced immunogenicity and the use of these novel proteins in the treatment of TNF related disorders.Type: GrantFiled: January 3, 2003Date of Patent: December 5, 2006Assignee: XencorInventors: Arthur J. Chirino, Peizhi Luo, Peter Colon McDonnell, Umesh Muchhal, Malu Lourdes Tansey
-
Patent number: 7141392Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.Type: GrantFiled: January 7, 2004Date of Patent: November 28, 2006Assignee: Queen Mary and Westfield CollegeInventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams
-
Patent number: 7138500Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: September 10, 1998Date of Patent: November 21, 2006Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
-
Patent number: 7132508Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 13, 2002Date of Patent: November 7, 2006Assignee: Schering CorporationInventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
-
Patent number: 7122639Abstract: Human chemokine Alpha-2-polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are method for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptides in a host.Type: GrantFiled: October 10, 2002Date of Patent: October 17, 2006Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Jeffrey Y. Su, Haodong Li
-
Patent number: 7118752Abstract: A method is described for using an a-type or b-type E domain of the human or trout IGF peptide for the inhibition of proliferation and invasiveness of a broad spectrum of malignant cells and for the inhibition of angiogenesis. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more malignant cells in a pharmaceutically acceptable composition, or alternatively, can be administered to one or more malignant cells by transforming the cells with exogenous nucleic acid that results in the expression of the E domain of IGF-1 in the cell.Type: GrantFiled: March 18, 2002Date of Patent: October 10, 2006Assignee: University of ConnecticutInventors: Thomas T. Chen, Maria J. M. Chen, Ya-Huei Kuo
-
Patent number: 7118888Abstract: An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to formulate nanospheres. In a murine model of RSV infection, intranasal administration with GXV results in significant induction of RSV-specific antibodies, nasal IgA antibodies, cytotoxic T lymphocytes, and IFN-? production in the lung and splenocytes. A single dose of GXV induces a drastic reduction of viral titers.Type: GrantFiled: February 12, 2002Date of Patent: October 10, 2006Assignees: University of South Florida Board of Trustees, Johns Hopkins UniversityInventors: Shyam S. Mohapatra, Mukesh Kumar, Shua-ku Huang, Kam Leong
-
Patent number: 7109041Abstract: A display and method of preparing 7-transmembrane and other receptors for real-time kinetic analysis of binding interactions. The invention includes display on beads and in micelles for multi-well and flow cytometric analysis. The invention is useful for ligand discovery and drug action discovery, and G-protein response in particular.Type: GrantFiled: March 21, 2002Date of Patent: September 19, 2006Assignee: Science & Technology Corporation @University of New MexicoInventors: Larry Sklar, Eric Prossnitz, Vilven Janeen, Donna Neldon
-
Patent number: 7101974Abstract: The invention relates to novel proteins with TNF-? antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-? related disorders, such as rheumatoid arthritis.Type: GrantFiled: October 15, 2001Date of Patent: September 5, 2006Assignee: XencorInventors: Bassil I. Dahiyat, Anton Filikov
-
Patent number: 7098002Abstract: Biologically active molecules are produced from their biologically inactive precursors by mutation of their native cleavage site to a site which is capable of being cleaved by a protease, and cleavage of the mutated molecule to yield a biologically active molecule.Type: GrantFiled: April 13, 2000Date of Patent: August 29, 2006Assignee: Yeda Research and Development Co. Ltd.Inventors: Menachem Rubinstein, Bianling Liu, Daniela Novick, Pierre Graber
-
Patent number: 7094593Abstract: This invention relates to mutant G protein-coupled receptors with improved G-protein coupling and receptor response, yeast cells expressing such receptors, vectors useful for making such cells, and methods of making and using same.Type: GrantFiled: September 1, 1999Date of Patent: August 22, 2006Assignees: BASF Aktiengesellschaft, The United States of America as represented by the Department of HealthInventors: Mark Henry Pausch, Jurgen Wess
-
Patent number: 7091401Abstract: The present invention provides a method of preparing epidermal growth factors in plants and transgenic plant seeds containing epidermal growth factors. The method provides an economical way to produce epidermal growth factors.Type: GrantFiled: December 20, 2002Date of Patent: August 15, 2006Assignee: Sembiosys Genetics Inc.Inventors: Maurice M. Moloney, Gijs Van Rooijen
-
Patent number: 7078027Abstract: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.Type: GrantFiled: May 2, 2002Date of Patent: July 18, 2006Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen
-
Patent number: 7063965Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention further provides for a ligandbody which specifically binds TIE-2 receptor. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth, differentiation or migration of cells expressing the TIE-2 receptor, including, but not limited to, hematopoietic precursor cells, a method of blocking the growth, differentiation or migration of cells expressing the TIE-2 receptor including, but not limited to, hematopoietic precursor cells, and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: June 25, 2003Date of Patent: June 20, 2006Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, George D. Yancopoulos
-
Patent number: 7064186Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: January 21, 2003Date of Patent: June 20, 2006Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Patent number: 7060261Abstract: The present invention relates to a novel CK?-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-5 protein. CK?-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-5 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: April 3, 2002Date of Patent: June 13, 2006Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Yi Li, Jian Ni, Craig A. Rosen, Steven M. Ruben
-
Patent number: 7060459Abstract: The present invention provides isolated TNF-inducible promoter sequences, expression vectors containing such promoter sequences, host cells transfected with such expression vectors, as well as methods for using the promoters, vectors, and host cells for identifying candidate compounds for treating or preventing autoimmune disorders or cancer, or for identifying promoters that are regulated by tumor necrosis factor.Type: GrantFiled: December 7, 2001Date of Patent: June 13, 2006Inventor: Juan Saus
-
Patent number: 7037676Abstract: The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.Type: GrantFiled: March 20, 2001Date of Patent: May 2, 2006Assignee: Bristol-Myers SquibbInventors: Pamela M. Carroll, Jian Chen, Chandra S. Ramanathan, Hong Xiao, Michael A. Bowen
-
Patent number: 7037491Abstract: The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.Type: GrantFiled: January 26, 2005Date of Patent: May 2, 2006Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Joo Young Chung, Sang Kyu Park, Sang Myoung Ju, Hyea Kyung Ahn, Seung Wook Lim, Woo Ik Chang, Seung Kook Park, Yeo Wook Koh, Ji Soo Park
-
Patent number: 7037685Abstract: Disclosed are created stable polypeptides which are capable of inducing the production of interferon-gamma by immunocompetent cells. The present polypeptides contain specific amino acid sequences usually derived from the wild-type polypeptides, being capable of the production of interferon-gamma, by replacing the cysteine(s) with different amino acid(s). The present polypeptides possess a stability and an activity of inducing the production of IFN-? by immunocompetent cells, both of which are significantly higher than those of the wild-type polypeptides. In addition to the activity, the present polypeptides can exhibit remarkable activities of inducing the formation of killer cells and enhancing thier cytotoxicities. The present polypeptides are easily obtainable by the process according to the present invention using recombinant DNA techniques.Type: GrantFiled: October 1, 2002Date of Patent: May 2, 2006Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kozo Yamamoto, Iwao Okamoto, Masashi Kurimoto
-
Patent number: 7030223Abstract: Novel polypeptides of human megakaryocyte stimulating factors (MSFs). Pharmaceutical compositions containing same, and methods for their preparation and use are provided.Type: GrantFiled: April 16, 2002Date of Patent: April 18, 2006Assignee: Genetics Institute LLCInventors: Katherine Turner, Steven C. Clark, Kenneth Jacobs, Rodney M. Hewick, Thomas G. Gesner
-
Patent number: 7029865Abstract: The present invention relates to rhesus monkey DNA molecules encoding the melanocortin-4 receptor protein, recombinant vectors comprising DNA molecules encoding rhesus MC-4R, recombinant host cells which contain a recombinant vectors encoding rhesus MC-4R, the rhesus MC-4R protein encoded by the DNA molecule, and methods of identifying selective agonists and antagonists of rhesus MC-4R.Type: GrantFiled: February 25, 2003Date of Patent: April 18, 2006Assignee: Merck & Co., Inc.Inventors: Douglas J. MacNeil, David H. Weinberg, Leonardus H. T. Van Der Ploeg
-
Patent number: 7018846Abstract: A display and method of preparing 7-transmembrane and other receptors for real-time kinetic analysis of binding interactions. The invention includes display on beads and in micelles for multi-well and flow cytometric analysis. The invention is useful for ligand discovery and drug action discovery, and G-protein response in particular.Type: GrantFiled: August 9, 1999Date of Patent: March 28, 2006Assignee: Science & Technology Corporation @ UNMInventors: Larry A. Sklar, Eric Prossnitz, Janeen Vilven, Donna Neldon
-
Patent number: 7001595Abstract: The present invention relates to deletion and substitution mutant polypeptides of human chemokine ?-7 (Ck?-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck?-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck?-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.Type: GrantFiled: October 1, 2002Date of Patent: February 21, 2006Assignees: Human Genome Sciences Inc., Beatson Institute for Cancer ResearchInventors: Theodora W. Salcedo, Vikram P. Patel, Robert John Benjamin Nibbs, Gerard John Graham
-
Patent number: 6994990Abstract: The present invention provides isolated highly active hedgehog proteins esterified with a fatty acid having from 14 to 20 carbon atoms at the N-terminal domain of the protein. The highly active hh proteins are particularly useful therapeutic agents for treating bone disorders and neurodegenerative diseases. Methods for obtaining the highly active modified hedgehog proteins are also provided.Type: GrantFiled: November 24, 1998Date of Patent: February 7, 2006Assignee: Curis, Inc.Inventors: Kurt Lang, Ulrike Leser, Tilman Seytter
-
Patent number: RE39788Abstract: Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.Type: GrantFiled: November 4, 2003Date of Patent: August 21, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: W. French Anderson, R. Michael Blaese, Steven A. Rosenberg